TrialJournal of cancer research and clinical oncology2024

Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.

Jie Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.